Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: A concurrent analysis of the serum and urine concentration data

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 6, 2008, Pages 677-684

  Fukuhara, K ^a   Ikawa, K ^a   Morikawa, N ^a   Kumagai, K ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Methotrexate; NONMEM; Population pharmacokinetics; Urine

Indexed keywords

METHOTREXATE;

ADULT; AGED; ARTICLE; BAYES THEOREM; COMPARTMENT MODEL; COMPUTER PROGRAM; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MEGADOSE; DRUG URINE LEVEL; FEMALE; HUMAN; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BAYES THEOREM; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FORECASTING; HUMANS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; NONLINEAR DYNAMICS; RETROSPECTIVE STUDIES; SOFTWARE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 55949096769     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00966.x     Document Type: Article

References (26)

1. Goldie JH, Price LA, Harrap KR (1972) Methotrexate toxicity: correlation with duration of administration: plasma levels, dose and excretion pattern. European Journal of Cancer, 8, 409 414.
2. Stoller RG, Hande KR, Jacobs SA et al. (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New England Journal of Medicine, 297, 630 634.
3. Evans WE, Pratt C, Taylor RH et al. (1979) Pharmacokinetic monitoring of high-dose methotrexate: early recognition of high-risk patients. Cancer Chemotherapy and Pharmacology, 3, 161 166.
4. Masson E, Relling MV, Synold TW et al. (1996) Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. Journal of Clinical Investigation, 97, 73 80.
5. Evans WE, Crom WR, Abromowitch M et al. (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. New England Journal of Medicine, 314, 471 477.
6. Iliadis A, Bachir-Raho M, Bruno R, Favre R (1985) Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. Journal of Pharmacokinetics and Biopharmaceutics, 13, 101 115.
7. Sabot C, Debord J, Roullet B et al. (1993) Bayesian estimation and population pharmacokinetic parameters of high dose methotrexate in osteosarcoma. Clinical Research and Regulatory Affairs, 10, 233 241.
8. Sabot C, Debord J, Roullet B, Marquet P, Merle L, Lachatre G (1995) Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics. International Journal of Clinical Pharmacology and Therapeutics, 33, 164 169.
9. Bagarry-Liégey D, Nicoara A, Duffaud F et al. (1996) Individual dose adjustment of high-dose methotrexate in clinical practice. La Revue de Médecine Interne, 17, 689 698.
10. Monjanel-Mouterde S, Lejeune C, Ciccolini J et al. (2002) Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer. Journal of Clinical Pharmacy and Therapeutics, 27, 189 195.
11. Rousseau A, Sabot C, Delepine N et al. (2002) Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clinical Pharmacokinetics, 41, 1095 1104.
12. Batey MA, Wright JG, Azzabi A et al. (2002) Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). European Journal of Cancer, 38, 1081 1089.
13. Faltaos DW, Hulot JS, Urien S et al. (2006) Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemotherapy and Pharmacology, 58, 626 633.
14. Joerger M, Huitema AD, Van den Bongard HJ et al. (2006) Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. British Journal of Clinical Pharmacology, 62, 71 80.
15. Campbell MA, Perrier DG, Dorr RT, Alberts DS, Finley PR (1985) Methotrexate: bioavailability and pharmacokinetics. Cancer Treatment Reports, 69, 833 838.
16. Shen DD, Azarnoff DL (1978) Clinical pharmacokinetics of methotrexate. Clinical Pharmacokinetics, 3, 1 13.
17. Morikawa N, Tsukamoto T, Nakano M et al. (1990) Changes in concentration of methotrexate (MTX) in serum and urine of patients with high-dose MTX in the citrovorum factor rescue therapy. Yakuzaigaku, 50, 42 52.
18. Morikawa N, Tsukamoto T, Nakano M et al. (1991) Pharmacokinetics of methotrexate and 7-hydroxyl-methotrexate in patients with high-dose methotrexate. Yakuzaigaku, 51, 115 122.
19. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31 41.
20. Livingston EH, Lee S (2001) Body surface area prediction in normal-weight and obese patients. American Journal of Physiology, Endocrinology and Metabolism, 281, E586 E591.
21. Yamaoka K, Nakagawa T, Tanaka H, Yasuhara M, Okumura K, Hori R (1985) A nonlinear multiple regression program, MULTI2 (BAYES), based on Bayesian algorithm for microcomputers. Journal of Pharmacobiodynamics, 8, 246 256.
22. Plard C, Bressolle F, Fakhoury M et al. (2007) A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 60, 609 620.
23. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics, 9, 503 512.
24. Pignon T, Lacarelle B, Duffaud F et al. (1994) Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemotherapy and Pharmacology, 33, 420 424.
25. Althaus BL, Winter ME (2003) Methotrexate (MTX). In : Winter ME, ed. Basic Clinical Pharmacokinetics, 4th edn. Philadelphia, PA : Lippincott Williams & Wilkins, Chapter 8, 274 293.
26. Lui CY, Lee MG, Chiou WL (1985) Clearance studies of methotrexate in dogs after multiple-rate infusion. Cancer Research, 45, 1545 1548.